drugset / Trial / NCT07774325

A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood

NCT07774325 ↗

Phase 1 Recruiting 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effects of multiple doses of Itraconazole and multiple doses of Ciclosporin on the pharmacokinetics of BI 3000202 in plasma following a single oral dose in healthy male trial participants.

Timeline

Start
2026-09-01
Primary completion
2026-10-06
Completion
2026-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3000202 Unknown — Oral
Subject Cyclosporine Peptide — —
Subject Itraconazole Small molecule — —

Indications

No indication recorded.